Related Experiment Video

Updated: Nov 25, 2025

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.2K

Roles of Interleukin-1 Receptor Antagonist in Prostate Cancer Progression

Yu-Ching Fan1, Kuan-Der Lee2, Yuan-Chin Tsai3,4

  • 1PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University and Academia Sinica, Taipei 110301, Taiwan.

Biomedicines
|December 16, 2020
PubMed
Abstract

Insights

CD11b-deficient leukocytes secrete interleukin-1 receptor antagonist (IL1RN), protecting prostate cancer cells from inflammation and promoting tumor growth. This natural anti-inflammatory factor plays a key role in the tumor microenvironment.

Area of Science:

  • Oncology
  • Immunology
  • Cell Biology

Background:

  • Inflammation is a known driver of tumor formation and progression.
  • Interleukin-1 receptor antagonist (IL1RN), a natural anti-inflammatory factor, was identified in the tumor microenvironment (TME) of mouse prostate cancer.
  • The function of IL1RN-secreting cells within the TME requires characterization.

Purpose of the Study:

  • To characterize the function of IL1RN-secreting cells in the prostate cancer TME.
  • To investigate the role of IL1RN in prostate cancer progression and inflammation.

Main Methods:

  • Comparison of tumors from two syngeneic mouse models.
  • Isolation and analysis of tumor-infiltrating leukocytes (TILs) based on CD11b expression.
  • Assessment of TIL and IL1RN proliferation functions using colony-formation assays and DNA synthesis measurements.
  • Analysis of conditioned media from TILs.

Main Results:

  • CD11b-deficient TILs (TILs/CD11b-) were found to secrete IL1RN and promote proliferation.
  • IL1RN's proliferative effects were confirmed in human castration-resistant prostate cancer (CRPC) cell lines and a normal epithelial cell line.
  • Androgen-sensitive LNCaP cells showed sensitivity to IL1β and IL1R1, while CRPC C4-2 cells did not.
  • IL1RN protected LNCaP cells from IL1β/IL1R1-induced cytotoxicity.

Conclusions:

  • TILs/CD11b- cells protect androgen-dependent prostate cancer cells from inflammatory damage.
  • IL1RN secreted by these cells contributes to prostate cancer malignant progression within the TME.
Keywords:
castration-resistant prostate cancerinterleukin-1 receptor antagonisttumor microenvironmenttumor-infiltrating leukocytes

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.2K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
328
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.6K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.3K